CSL Limited (CSJ) - Net Assets
Based on the latest financial reports, CSL Limited (CSJ) has net assets worth €20.55 Billion EUR as of December 2024. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€38.45 Billion) and total liabilities (€17.90 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €20.55 Billion |
| % of Total Assets | 53.44% |
| Annual Growth Rate | 18.99% |
| 5-Year Change | 155.41% |
| 10-Year Change | 519.23% |
| Growth Volatility | 22.89 |
CSL Limited - Net Assets Trend (2014–2025)
This chart illustrates how CSL Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CSL Limited (2014–2025)
The table below shows the annual net assets of CSL Limited from 2014 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | €21.41 Billion | +10.34% |
| 2024-06-30 | €19.40 Billion | +8.84% |
| 2023-06-30 | €17.83 Billion | +22.28% |
| 2022-06-30 | €14.58 Billion | +73.93% |
| 2021-06-30 | €8.38 Billion | -11.88% |
| 2020-06-30 | €9.51 Billion | +27.02% |
| 2019-06-30 | €7.49 Billion | +35.65% |
| 2018-06-30 | €5.52 Billion | +34.21% |
| 2017-06-30 | €4.11 Billion | +18.98% |
| 2016-06-30 | €3.46 Billion | +25.85% |
| 2015-06-30 | €2.75 Billion | -13.13% |
| 2014-06-30 | €3.16 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to CSL Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 239.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €17.74 Billion | 91.77% |
| Other Components | €1.59 Billion | 8.23% |
| Total Equity | €19.34 Billion | 100.00% |
CSL Limited Competitors by Market Cap
The table below lists competitors of CSL Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Occidental Petroleum Corporation
NYSE:OXY
|
$45.39 Billion |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
$45.51 Billion |
|
Great-West Lifeco Inc.
TO:GWO
|
$45.61 Billion |
|
COMPASS GROUP
F:XGR
|
$45.63 Billion |
|
RIO Tinto Ltd
AU:RIO
|
$45.34 Billion |
|
Maruti Suzuki India Limited
NSE:MARUTI
|
$45.34 Billion |
|
Axis Bank Limited
NSE:AXISBANK
|
$45.34 Billion |
|
Fannie Mae
LSE:0IL0
|
$45.34 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CSL Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 17,363,000,000 to 19,335,000,000, a change of 1,972,000,000 (11.4%).
- Net income of 3,002,000,000 contributed positively to equity growth.
- Dividend payments of 1,434,000,000 reduced retained earnings.
- New share issuances of 17,000,000 increased equity.
- Other factors increased equity by 387,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €3.00 Billion | +15.53% |
| Dividends Paid | €1.43 Billion | -7.42% |
| Share Issuances | €17.00 Million | +0.09% |
| Other Changes | €387.00 Million | +2.0% |
| Total Change | €- | 11.36% |
Book Value vs Market Value Analysis
This analysis compares CSL Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.06x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 9.09x to 2.06x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-06-30 | €9.07 | €82.45 | x |
| 2018-06-30 | €12.20 | €82.45 | x |
| 2019-06-30 | €16.52 | €82.45 | x |
| 2020-06-30 | €20.95 | €82.45 | x |
| 2021-06-30 | €18.42 | €82.45 | x |
| 2022-06-30 | €30.26 | €82.45 | x |
| 2023-06-30 | €32.73 | €82.45 | x |
| 2024-06-30 | €35.93 | €82.45 | x |
| 2025-06-30 | €39.93 | €82.45 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CSL Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 15.53%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 19.46%
- • Asset Turnover: 0.39x
- • Equity Multiplier: 2.04x
- Recent ROE (15.53%) is below the historical average (31.81%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 41.33% | 24.50% | 0.85x | 1.99x | €990.80 Million |
| 2015 | 50.20% | 25.26% | 0.85x | 2.33x | €1.10 Billion |
| 2016 | 48.40% | 21.02% | 0.78x | 2.95x | €1.33 Billion |
| 2017 | 42.27% | 20.22% | 0.73x | 2.88x | €1.33 Billion |
| 2018 | 42.38% | 22.78% | 0.70x | 2.64x | €1.79 Billion |
| 2019 | 36.54% | 22.55% | 0.69x | 2.35x | €1.99 Billion |
| 2020 | 32.21% | 23.10% | 0.59x | 2.37x | €2.11 Billion |
| 2021 | 28.34% | 23.14% | 0.57x | 2.17x | €1.54 Billion |
| 2022 | 15.47% | 21.49% | 0.37x | 1.94x | €796.95 Million |
| 2023 | 13.90% | 16.65% | 0.36x | 2.30x | €615.40 Million |
| 2024 | 15.22% | 17.99% | 0.39x | 2.19x | €905.70 Million |
| 2025 | 15.53% | 19.46% | 0.39x | 2.04x | €1.07 Billion |
Industry Comparison
This section compares CSL Limited's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $384,236,557
- Average return on equity (ROE) among peers: -692.38%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CSL Limited (CSJ) | €20.55 Billion | 41.33% | 0.87x | $45.38 Billion |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $22.67 Million |
| PreveCeutical Medical Inc (18H) | $-4.10 Million | 0.00% | 0.00x | $3.34 Million |
| IDORSIA AG (19T) | $-1.14 Billion | 0.00% | 0.00x | $978.02 Million |
| Argen-X (1AE) | $538.39 Million | -12.38% | 0.07x | $44.01 Billion |
| ONCOARENDI THERAP ZY-01 (1B1) | $103.41 Million | -30.26% | 0.10x | $24.94 Million |
| Flerie AB (publ) (1NP1) | $4.20 Billion | -5.43% | 0.01x | $231.62 Million |
| NUFORMIX PLC LS -001 (1RT) | $5.69 Million | -22.04% | 0.06x | $1.53 Million |
| 1S90 (1S90) | $131.51 Million | -49.87% | 1.70x | $70.17 Million |
| Strategic Partners A/S (1TB0) | $9.34 Million | -6708.84% | 17.55x | $3.69 Million |
| Entheon Biomedical Corp. (1XU) | $315.75K | -95.01% | 0.27x | $486.08K |
About CSL Limited
CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma produ… Read more